Back to results
US 2023/0390331 A1Published application
Biomarkers For Neurogenerative Disease
AssigneesNeuvivo, Inc., The Regents of the University of California
InventorsArasteh Azhir, Michael S. McGrath, Bruce D. FORREST
Life of this patent
Estimating the term…
Abstract
Described herein are methods of monitoring and treating a subject with ALS based on biomarkers.
Claims24
1-69. (canceled)
A method comprising:
- a) identifying that a subject has a level of TGFB1 associated with ALS;
- and
- b) based on the identifying that the subject has the level of TGFB1 associated with ALS, determining that the subject is eligible for sodium chlorite therapy for the ALS.
(canceled)
A method of treating ALS in a subject in need thereof, the method comprising:
- a) identifying that a subject has a level of TGFB1 associated with ALS;
- and
- b) based on the identifying that the subject has the level of TGFB1 associated with ALS, administering to the subject an amount of sodium chlorite that is therapeutically-effective for ALS.
(canceled)
92-153. (canceled)
Dependencies are inferred from the claim text.